Similar articles

• Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?

  Berkowitsch A, Neumann T, Kuniss M, Janin S, Wojcik M, Zaltsberg S, Mitrovic V, Pitschner HF. Berkowitsch A, et al. Pacing Clin Electrophysiol. 2010 Sep;33(9):1101-11. doi: 10.1111/j.1540-8159.2010.02769.x. Pacing Clin Electrophysiol. 2010. PMID: 20487340
• Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

  Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Savelieva I, et al. Europace. 2011 Mar;13(3):308-28. doi: 10.1093/europace/eur002. Europace. 2011. PMID: 21345926 Review.
• Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation.

  Tayebjee MH, Creta A, Moder S, Hunter RJ, Earley MJ, Dhinoja MB, Schilling RJ. Tayebjee MH, et al. Europace. 2010 Nov;12(11):1537-42. doi: 10.1093/europace/euq284. Epub 2010 Aug 2. Europace. 2010. PMID: 20682557
• Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations.

  Naccarelli GV, Curtis AB. Naccarelli GV, et al. J Cardiovasc Pharmacol Ther. 2010 Sep;15(3):244-56. doi: 10.1177/1074248410370964. Epub 2010 Jun 18. J Cardiovasc Pharmacol Ther. 2010. PMID: 20562374 Review.
• The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.

  Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, Wilber DJ. Al Chekakie MO, et al. J Cardiovasc Electrophysiol. 2007 Sep;18(9):942-6. doi: 10.1111/j.1540-8167.2007.00887.x. Epub 2007 Jun 25. J Cardiovasc Electrophysiol. 2007. PMID: 17593228